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Background/Aims: The eradication rate of the first-line standard triple therapy (STT) for Helicobacter pylori (H. pylori) infection 
has decreased since 2000; therefore, other first-line therapies are required. This study was aimed at investigating the efficacy of bis-
muth-containing quadruple therapy (PBMT) for first-line H. pylori eradication compared to STT, sequential therapy (SQT), and 
concomitant therapy (CT).
Materials and Methods: The Ovid-MEDLINE, Koreamed, EMBASE, KMBASE, and Cochrane Library databases were searched 
from January 2008 to July 2018. All identified randomized controlled trials (RCTs) comparing PBMT and non-PBMT for first-line 
H. pylori eradication therapy were included in the final analysis. 
Results: A total of 3,653 patients from seven RCTs were enrolled. The pooled eradication rates of PBMT by intention-to-treat (ITT) 
and per-protocol (PP) analyses were 82.1% (95% CI, 68.2~90.8%) and 88.8% (95% CI, 77.1~94.9%), respectively. However, no 
statistically significant difference was observed in eradication rates of the 10- or 14-day PBMT as compared to 14-day STT, 10-day 
SQT, and 10-day CT in ITT and PP analyses. PBMT was significantly higher in adverse events than in the other eradication regimens 
(RR, 1.64; 95% CI, 1.11~2.44). Considerable heterogeneity in adverse events was observed among studies (χ2=88.7; P<0.001, 
I2=93%).
Conclusions: PBMT can be the first-line treatment for H. pylori eradication in Korea when other first-line options, including STT, 
SQT, or CT, are unavailable due to their high adverse event rates. (Korean J Helicobacter Up Gastrointest Res 2021;21:48-58)
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INTRODUCTION
As of 2015, the global prevalence of Helicobacter pylo-
ri (H. pylori) was approximately 4.4 billion.1 This com-
mon infection is well known to cause gastritis, peptic ul-
cers, gastric mucosa-associated lymphoid tissue lympho-
ma, and gastric cancer.2 Therefore, effective eradication 
therapy is crucial for building public health, particularly 
in high H. pylori prevalence areas, including Korea.
According to Korean guidelines for the diagnosis and 
treatment of H. pylori infection, which were revised in 
2013, standard triple therapy, comprising proton pump 
inhibitors (PPIs), amoxicillin, and clarithromycin, is the 
recommended first-line eradication regimen for H. pylori 
infection.3 Unfortunately, the efficacy of the standard tri-
ple therapy is declining worldwide, and this tendency is 
also observed in Korea.4-6 The H. pylori eradication rates 
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in Korea using standard triple therapy were 84.9~87.5% 
from 2001 to 2007 and 80.0~81.4% from 2008 to 2010 
(P<0.0001), presenting a decreasing trend for the last 10 
years.5
Several recognized guidelines recommended that stand-
ard triple therapy, sequential therapy (SQT), concomitant 
therapy (CT), bismuth-containing quadruple, or non-bis-
muth-containing quadruple therapies are a recommended 
first-line treatment option.7,8 In the aforementioned re-
vised Korean guidelines, when clarithromycin resistance is 
suspected, bismuth-containing quadruple therapy is used 
as the first-line therapy; however, it is generally recom-
mended as a second-line regimen to eradicate H. pylori.3
Bismuth-containing quadruple therapy is an effective reg-
imen for H. pylori eradication. However, the efficacy of bis-
muth-containing quadruple therapy as a first-line treatment 
has depended on the type of eradication regimens and dura-
tion of therapies in two network meta-analyses of the 
randomized controlled trials (RCTs).9,10 With this back-
ground, a meta-analysis was conducted to evaluate the effi-
cacy and safety of bismuth-containing quadruple therapy for 
first-line H. pylori eradication and compare it to standard 
triple therapy, SQT, and CT, which are commonly used as 
first-line eradication therapies. 
MATERIALS AND METHODS
1. Search strategy 
We searched Ovid-MEDLINE, KoreaMed, EMBASE, KMBASE, 
and Cochrane Library from January 2008 to July 2018. The 
exploring key words were “Helicobacter pylori or Helico- 
bacter infection” and “bismuth based quadruple therapy, bis-
muth therapy, or bismuth treat”. Languages were limited to 
English and Korean. The reporting of the current study follows 
the PRISMA guidelines.11
2. Study selection 
Studies were included in the meta-analysis if the fol-
lowing criteria were met: 1) RCTs; 2) bismuth-containing 
quadruple therapy as a first-line eradication therapy; 3) H. 
pylori infection was identified by at least one of the fol-
lowing modalities: rapid urease test, urea breath test, his-
tology, or culture; 4) successful eradication of H. pylori 
infection was clarified with previous mentioned modal-
ities; and 5) bismuth-containing quadruple therapy con-
sisting of PPIs, bismuth compounds, metronidazole, and 
tetracycline.
Non-RCTs, studies with second-line treatment using bis-
muth-containing quadruple therapy, bismuth-containing 
regimens including PyleraⓇ (Allegran, Dublin, Ireland), con-
trol groups consisting of the same regimens as the inter-
vention group with different duration or different doses, 
reviews, case reports, letters, editorials, and abstracts were 
excluded.
Two investigators (S.E.K. and H.K.J.) separately re-
viewed the results of the search, and selected the in-
cluded studies. Disagreement was resolved by consensus.
3. Data extraction 
The following information was collected from the en-
rolled studies: 1) name of the first author, year of pub-
lication, country, and trial types; 2) number of subjects in 
each study according to therapeutic regimens, mean age, 
therapeutic regimens, duration of regimens, and funding; 
3) diagnostic methods of confirming H. pylori infection 
and eradication, and eradication follow-up period; and 
4) number of subjects who were successfully treated in 
each regimen, eradication rates of both intention-to-treat 
(ITT) and per-protocol (PP) analyses, and adverse events.
4. Risk of bias
Two investigators (S.E.K. and H.K.J.) independently as-
sessed the potential bias of enrolled studies using Cochrane 
Handbook for Systemic Reviews in Intervention.12 The as-
sessment tool of Cochrane Collaboration was categorized 
as randomization, allocation concealment, blinding of par-
ticipants and personnel, blinding of outcome assessment, in-
complete outcome data, and selective outcome data.
5. Statistical analysis
All statistical analyses were performed with Review 
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Records excluded by title or abstract screening
(n=172)
Records excluded according to selection criteria
(n=25)
- No bismuth-containing quadruple therapy
  (PPIs, bismuth, metronidazole, and tetracycline)
  given (n=7)
- Using Pylera® (n=3)
- Meta-analysis (n=8)
- Not randomized controlled trial (n=5)
- Comparison with same or similar regimens (n=2)
Records identified




























Fig. 1. Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) flow diagram of the study selection. PPIs, proton pump 
inhibitors.
Manager version 5.3 software (Revman; The Cochrane 
Collaboration Oxford, UK). The pooled eradication rate with 
95% CI in bismuth-containing quadruple therapy and 
non-bismuth-containing quadruple therapy was calculated. 
Thereafter, subgroup analyses were conducted according to 
the eradication regimens. The assessments of the subgroup 
analyses and adverse events were expressed as the RR with 
95% CI. We investigated heterogeneity between studies by 
using I2 statistics. We considered I2 value of 25%, 50%, and 
75% to be low, moderate, and high degrees of heterogeneity, 
respectively. When high heterogeneity occurred, we calcu-
lated RRs using random-effect models. We used both ITT 
and PP analyses for clinical outcomes. A P<0.05 was sug-
gested as being statistically significant.
RESULTS
1. Study selection
A total of 204 studies were reviewed. Fig. 1 shows the 
flow diagram of the literature search. Subsequently, we 
excluded 172 studies after reviewing the title or abstract, 
and we reviewed full articles or abstracts for 32 studies. 
Among them, 25 studies were excluded according to the 
selection criteria. Finally, seven RCTs with 3,653 patients 
were enrolled for meta-analysis.13-19 The study design of 
five trials was multiple arms; therefore, the data of the 
groups that accorded with the inclusion criteria were se-
lected and included for analysis. 
2. Characteristics of studies and risk of bias
Table 1 presents the main characteristics of the studies. 
All studies used a first-line bismuth-containing quadruple 
therapy consisting of PPIs (pantoprazole, rabeprazole, or 
lansoprazole), bismuth compounds (bismuth subcitrate, 
bismuth tripotassium dicitrate, bismuth potassium citrate, 
colloidal bismuth subcitrate, or bismuth subsalicylate), 
metronidazole, and tetracycline (PBMT). Patients who re-
ceived PBMT were 1,206, and 2,447 patients were treated 
with non-PBMT regimens. Among the non-PBMT regimen 
groups, 753 patients of three trials in standard triple ther-
apy group, 230 patients in two trials in the SQT group, 
and 770 patients of three trials in the CT group were eli-
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Tsay et al.13 
(2017)
Taiwan Pantoprazole 40 mg 
bid, bismuth 
subcitrate 120 mg 
qid, metronidazole 
250 mg qid, 
tetracycline 500 mg 
qid (n=164)
14 -First 7 days: pantoprazole 40 mg bid, 
amoxicillin 1 g bid
-Second 7 days: pantoprazole 40 mg bid, 
amoxicillin 1 g bid, clarithromycin 500 mg 









Turkey Rabeprazole 20 mg bid, 
bismuth subcitrate 
120 mg qid, 
metronidazole 500 
mg tid, tetracycline 
500 mg qid (n=100)
14 Rabeprazole 20 mg tid, amoxicillin 750 mg 
tid (n=100)
14 Histology Stool 
antigen 
test
Liou et al.15 
(2016)
Taiwan Lansoprazole 30 mg 
bid, bismuth 
tripotassium 
dicitrate 300 mg qid, 
metronidazole 500 
mg tid, tetracycline 
500 mg qid (n=540)
10 Group 1: lansoprazole 30 mg bid, 
amoxicillin 1 g bid, clarithromycin 500 mg 
bid, metronidazole 500 mg bid (n=540)
Group 2: lanroprazole 30 mg bid, 












Turkey Rabeprazole 40 mg bid, 
bismuth potassium 
citrate 220 mg bid, 
metronidazole 500 
mg tid, tetracycline 
500 mg tid (n=130)
10 Group 1 (n=130):
-First 5 days: rabeprazole 40 mg bid, 
amoxicillin 1 g bid
-Second 5 days: rabeprazole 40 mg bid, 
clarithromycin 500 mg bid, metronidazole 
500 mg tid
Group 2 (n=130): rabeprazole 40 mg bid, 
amoxicillin 1 g bid, clarithromycin 500 mg 







Turkey Lansoprazole 30 mg 
bid, colloidal 
bismuth subcitrate 
300 mg qid, 
metronidazole 500 
mg tid, tetracycline 
500 mg qid (n=53)
14 Group 1 (n=42): lanroprazole 30 mg bid, 
colloidal bismuth subcitrate 300 mg qid, 
amoxicillin 1 g bid, levofloxacin 500 mg qd
Group 2 (n=54): lanroprazole 30 mg bid, 
colloidal bismuth subcitrate 300 mg qid, 











Turkey Pantoprazole 40 mg 
bid, bismuth 
subsalicylate 300 mg 
qid, metronidazole 
500 mg tid, 
tetracycline 500 mg 
qid (n=100)
14 Group 1 (n=100): pantoprazole 40 mg bid, 
amoxicillin 1 g bid, clarithromycin 500 mg 
bid
Group 2 (n=100): pantoprazole 40 mg bid, 
amoxicillin 1 g bid, metronidazole 500 mg 
bid
Group 3 (n=100):
-First 5 days: pantoprazole 40 mg bid, 
amoxicillin 1 g bid
-Second 5 days: pantoprazole 40 mg bid, 
tetracycline 500 mg qid, metronidazole 
500 mg bid
Group 4 (n=100): pantoprazole 40 mg bid, 
amoxicillin 1 g bid, tetracycline 500 mg qid, 



































Turkey Lansoprazole 30 mg 
bid, bismuth 
subcitrate 300 mg 
qid, metronidazole 
500 mg bid, 
tetracycline 500 mg 
qid (n=119)
10 Group 1 (n=113): lanroprazole 30 mg bid, 
amoxicillin 1 g bid, clarithromycin 500 mg 
bid
Group 2 (n=117): lanroprazole 30 mg bid, 
ranitidine bismuth citrate 400 mg bid, 
tetracycline 500 mg qid, metronidazole 
500 mg bid
Group 3 (n=115): lanroprazole 30 mg bid, 








bid, twice a day; qid, four times a day; RUT, rapid urease test; tid, three times a day; UBT, urea breath test; qd, once a day.
Study or subgroup
10-/14-day PBMT 14-day STT Weight 
(%)
Risk ratio Risk ratio Risk of bias
Events Total Events Total M-H, random, 95% CI M-H, random, 95% CI    A  B  C  D  E F G
Gungor et al.18 (2015) 62 100 42 100 30.4 1.48 (1.12, 1.95)
0.01 0.1 1 10 100
Liou et al.15 (2016) 488 540 452 540 42.3 1.08 (1.03, 1.13)
Songür et al.19 (2009) 56 119 37 113 27.3 1.44 (1.04, 1.99)
Total (95% CI) 759 753 100.0 1.28 (0.97, 1.70)
Total events 606 531
Heterogeneity: Tau2=0.05, chi2=10.14, df=2 (P=0.006), I2=80%




10-/14-day PBMT 14-day STT Weight 
(%)
Risk ratio Risk ratio Risk of bias
Events Total Events Total M-H, random, 95% CI M-H, random, 95% CI    A  B  C  D  E F G
Gungor et al.18 (2015) 62 80 42 87 32.4 1.61 (1.25, 2.06)
0.01 0.1 1 10 100
Liou et al.15 (2016) 461 480 446 508 37.7 1.09 (1.05, 1.14)
Songür et al.19 (2009) 56 102 37 104 29.9 1.54 (1.13, 2.11)
Total (95% CI) 662 699 100.0 1.37 (0.95, 1.99)
Total events 579 525
Heterogeneity: Tau2=0.10, chi2=20.95, df=2 (P<0.0001), I2=90%
Test for overall effect: Z=1.67 (P=0.10) Favours 10-/14-day  Favours 14-day STT
PBMT 
 B
Fig. 2. Forest plot of Helicobacter pylori eradication of 10- or 14-day bismuth-containing quadruple therapy (PMBT) vs. 14-day standard triple
therapy (STT) as the first-line therapy. (A) Intention-to-treat analysis. (B) Per-protocol analysis. Risk of bias: A, random sequence generation
(selection bias); B, allocation concealment (selection bias); C, blinding of participants and personnel (performance bias); D, blinding of outcome
assessment (detection bias); E, incomplete outcome data (attrition bias); F, selective reporting (reporting bias); G, other bias. M-H, Mantel-Haenszel
test.
gible to subgroup analysis for eradication efficacy. The 
risks of bias assessment in seven trials are shown in 
Supplementary Table 1.
3. Eradication rates of PBMT
The pooled eradication rates of PBMT were 82.1% (95% 
CI, 68.2~90.8%) in ITT analysis and 88.8% (95% CI, 
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Study or subgroup
10-/14-day PBMT 10-day SQT Weight 
(%)
Risk ratio Risk ratio Risk of bias
Events Total Events Total M-H, random, 95% CI M-H, random, 95% CI    A  B  C  D  E F G
Gungor et al.18 (2015) 62 100 71 100   34.6 0.87 (0.72, 1.06)
0.01 0.1 1 10 100
Kefeli et al.16 (2016) 114 130 113 130   65.4 1.01 (0.92, 1.11)
Total (95% CI) 230 230 100.0 0.96 (0.83, 1.12)
Total events 176 184
Heterogeneity: Tau2=0.01, chi2=2.08, df=1 (P=0.15), I2=52%




10-/14-day PBMT 10-day SQT Weight 
(%)
Risk ratio Risk ratio Risk of bias
Events Total Events Total M-H, random, 95% CI M-H, random, 95% CI    A  B  C  D  E F G
Gungor et al.18 (2015) 62 80 71 88   13.1 0.96 (0.82, 1.12)
0.01 0.1 1 10 100
Kefeli et al.16 (2016) 114 121 113 119   86.9 0.99 (0.93, 1.05)
Total (95% CI) 201 207 100.0 0.99 (0.93, 1.05)
Total events 176 184
Heterogeneity: Tau2=0.00, chi2=0.22, df=1 (P=0.64), I2=0%
Test for overall effect: Z=0.42 (P=0.67) Favours 10-/14-day   Favours 10-day SQT
PBMT 
 B
Fig. 3. Forest plot of Helicobacter pylori eradication of 10- or 14-day bismuth-containing quadruple therapy (PBMT) vs. 10-day sequential therapy 
(SQT) as the first-line therapy. (A) Intention-to-treat analysis. (B) Per-protocol analysis. Risk of bias: A, random sequence generation (selection 
bias); B, allocation concealment (selection bias); C, blinding of participants and personnel (performance bias); D, blinding of outcome assessment 
(detection bias); E, incomplete outcome data (attrition bias); F, selective reporting (reporting bias); G, other bias. M-H, Mantel-Haenszel test.
77.1~94.9%) in PP analysis. The pooled eradication rates 
of non-PBMT were 77.7% (95% CI, 62.7~88.0%) and 
83.3% (95% CI, 68.0~92.1%) in ITT and PP analyses, 
respectively. In terms of the treatment duration, the 
pooled eradication rates of 10-day PBMT were 79.6% 
(95% CI, 47.4~94.4%) and 88.6% (95% CI, 54.7~98.0%) in 
ITT and PP analyses, respectively. The pooled eradication 
rates of 14-day PBMT were 83.9% (95% CI, 66.9~93.1%) 
in ITT analysis and 88.9% (95% CI, 77.2~95.0%) in PP 
analysis. 
4. Eradication rates between PBMT and standard 
triple therapy
Of three trials, 759 patients were prescribed PBMT for 
10 or 14 days, and 753 patients received standard triple ther-
apy for 14 days (Fig. 2). When we compared eradication 
rates between 10- or 14-day PBMT and 14-day standard 
triple therapy, the differences were not statistically sig-
nificant in ITT and PP analyses (ITT analysis: RR, 1.28; 95% 
CI, 0.97~1.70; P=0.08; PP analysis: RR, 1.37; 95% CI, 
0.95~1.99; P=0.10). However, heterogeneity among the 
studies was high in the ITT and PP analyses (ITT analysis: 
χ2=10.14, P=0.006, I2=80%; PP analysis: χ2=20.95, P<0.001, 
I2=90%).
5. Eradication rates between PBMT and SQT
Each of 230 patients were treated with 10- or 14-day 
PBMT and 10-day SQT (Fig. 3). Eradication rates between 
10- or 14-day PBMT and 10-day SQT were not sig-
nificantly different in ITT and PP analyses (ITT analysis: 
RR, 0.96; 95% CI, 0.83~1.12; P=0.59; PP analysis: RR, 
0.99; 95% CI, 0.93~1.05; P=0.67). Heterogeneity between 
the studies was moderate in ITT analysis (χ2=2.08, 
P=0.15, I2=52%), and low in PP analysis (χ2=0.22, P=0.64, 
I2=0%).
6. Eradication rates between PBMT and CT
Each of 770 patients received PBMT for 10 or 14 days 
and CT for 10 days (Fig. 4). There were no significant dif-
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Study or subgroup
10-/14-day PBMT 10-day CT Weight 
(%)
Risk ratio Risk ratio Risk of bias
Events Total Events Total M-H, random, 95% CI M-H, random, 95% CI    A  B  C  D  E F G
Gungor et al.18 (2015) 62 100 72 100 13.6 0.86 (0.71, 1.05)
0.01 0.1 1 10 100
Kefeli et al.16 (2016) 114 130 113 130 34.4 1.01 (0.92, 1.11)
Liou et al.15 (2016) 488 540 464 540 52.0 1.05 (1.01, 1.10)
Total (95% CI) 770 770 100.0 1.01 (0.93, 1.10)
Total events 664 649
Heterogeneity: Tau2=0.00, chi2=4.57, df=2 (P=0.10), I2=56%




10-/14-day PBMT 10-day CT Weight 
(%)
Risk ratio Risk ratio Risk of bias
Events Total Events Total M-H, random, 95% CI M-H, random, 95% CI    A  B  C  D  E F G
Gungor et al.18 (2015) 62 80 72 86 13.0 0.93 (0.80, 1.08)
0.01 0.1 1 10 100
Kefeli et al.16 (2016) 114 121 113 118 37.8 0.98 (0.93, 1.04)
Liou et al.15 (2016) 461 480 453 494 49.2 1.05 (1.01, 1.08)
Total (95% CI) 681 698 100.0 1.01 (0.95, 1.07)
Total events 637 638
Heterogeneity: Tau2=0.00, chi2=5.51, df=2 (P=0.06), I2=64%
Test for overall effect: Z=0.21 (P=0.83) Favours 10-/14-day   Favours 10-day CT
PBMT 
 B
Fig. 4. Forest plot of Helicobacter pylori eradication with 10- or 14-day bismuth-containing quadruple therapy (PBMT) vs. 10-day concomitant 
therapy (CT) as the first-line therapy. (A) Intention-to-treat analysis. (B) Per-protocol analysis. Risk of bias: A, random sequence generation 
(selection bias); B, allocation concealment (selection bias); C, blinding of participants and personnel (performance bias); D, blinding of outcome 
assessment (detection bias); E, incomplete outcome data (attrition bias); F, selective reporting (reporting bias); G, other bias. M-H, Mantel-Haenszel 
test.
Study or subgroup
PBMT Other Weight 
(%)
Risk ratio Risk ratio Risk of bias
Events Total Events Total M-H, random, 95% CI M-H, random, 95% CI    A  B  C  D  E F G
Gokcan et al.17 (2016) 29 53 68 96 15.0 0.77 (0.59, 1.02)
0.01 0.1 1 10 100
Gungor et al.18 (2015) 18 80 50 357 13.0 1.61 (0.99, 2.60)
Kefeli et al.16 (2016) 54 130 103 260 15.2 1.05 (0.81, 1.35)
Liou et al.15 (2016) 358 533 561 1,070 16.0 1.28 (1.18, 1.39)
Sapmaz et al.14 (2017) 84 98 13 98 12.7 6.46 (3.87, 10.79)
Songür et al.19 (2009) 26 102 74 313 14.0 1.08 (0.73, 1.59)
Tsay et al.13 (2017) 91 164 26 166 14.1 3.54 (2.43, 5.17)
Total (95% CI) 1,160 2,360 100.0 1.64 (1.11, 2.44)
Total events 660 895
Heterogeneity: Tau2=0.25, chi2=88.72, df=6 (P<0.00001), I2=93%
Test for overall effect: Z=2.46 (P=0.01) PBMT   Other
Fig. 5. Forest plot of Helicobacter pylori eradication with bismuth-containing quadruple therapy (PBMT) vs. non-bismuth-containing quadruple 
therapy as the first-line therapy. Risk of bias: A, random sequence generation (selection bias); B, allocation concealment (selection bias); C, blinding 
of participants and personnel (performance bias); D, blinding of outcome assessment (detection bias); E, incomplete outcome data (attrition bias); 
F, selective reporting (reporting bias); G, other bias. M-H, Mantel-Haenszel test.
ferences between 10- or 14-day PBMT and 10-day CT 
groups in either analyses (ITT analysis: RR, 1.01; 95% CI, 
0.93~1.10; P=0.83; PP analysis: RR, 1.01; 95% CI, 
0.95~1.07; P=0.83). Moderate heterogeneity in the studies 
was revealed in both the ITT and PP analyses (ITT 
analysis: χ2=4.57, P=0.10, I2=56%; PP analysis: χ2=5.51, 




All seven trials identified adverse events with treatment. 
With regard to the duration of the treatment, the pooled 
adverse event rate of 10-day PBMT were 44.6% (95% CI, 
22.5~69.1%) and those of 14-day PBMT were 55.9% (95% 
CI, 27.6~80.8%). The meta-analysis of these trials revealed 
that the frequency of adverse events was significantly 
higher in patients with PBMT than in those with 
non-PBMT, and the pooled RR for adverse events was 
1.64 (95% CI, 1.11~2.44; P=0.01) (Fig. 5). However, sig-
nificant heterogeneity in adverse event was observed in 
the trials (χ2=88.7, P<0.001, I2=93%). 
DISCUSSION
Eradication rate of H. pylori is closely related to antibiotics 
resistance. Among them, the resistance of clarithromycin re-
duces the success rate of H. pylori eradication. A recent 
meta-analysis reported that the pooled RR of the eradication 
rate was 0.682 (95% CI, 0.636~0.731) in patients with H. 
pylori strains sensitive versus resistant to clarithromycin, 
whereas the pooled RR of the eradication rate was 0.843 
(95% CI, 0.810~0.877) and 0.794 (95% CI, 0.669~0.941) in 
patients with H. pylori strains sensitive versus resistant to 
metronidazole and levofloxacin, respectively.20 Compared to 
other antibiotics, clarithromycin had the most pervasive in-
fluence in eradication rates.
High clarithromycin resistance areas are commonly de-
fined as the clarithromycin resistance rate of H. pylori, 
which is at least 15%.7 Clarithromycin resistance has in-
creased during the last decade in Korea,21 and recent 
Korean studies still presented that clarithromycin resist-
ance rates were 17.8~31.0%.22,23 At least for first-line H. 
pylori eradication therapy, successful eradication rates 
should be more than 80% in ITT analysis and more than 
90% in PP analysis.24 Established guidelines recommended 
that bismuth-containing quadruple or non-bismuth-con-
taining quadruple therapies are appropriate as the 
first-line H. pylori eradication therapy in areas of high 
clarithromycin resistance.7,8 This meta-analysis revealed 
that the pooled eradication rate for PBMT as a first-line 
eradication therapy was 82.1% and 88.8% in ITT and PP 
analyses. Although the eradication rate in PP analysis did 
not reach 90%, the effect of PBMT was assumed to be 
sufficient because the eradication rate was almost 90%.
Nonetheless, when we compared the eradication rates 
between PBMT and other widely used first-line erad-
ication regimens, there were no statistically significant 
differences of eradication rates in 10- or 14-day PBMT 
with 10-day SQT (RR, 0.99; 95% CI, 0.93~1.05), 10-day 
CT (RR, 1.01; 95% CI, 0.95~1.07), or even 14-day stand-
ard triple therapy (RR, 1.37; 95% CI, 0.95~1.99). Our re-
sults indicate that 14-day standard triple therapy, 10-day 
SQT, and 10-day CT are not inferior to 10- or 14-day 
PBMT.
Duration of treatment can affect the H. pylori erad-
ication rate, and regimens of longer duration had higher 
eradication rates than did regimens of shorter duration.10 
In terms of standard triple therapy, 14-day standard triple 
therapy (OR, 1.72; 95% CI, 1.37~2.17) and 10-day stand-
ard triple therapy (OR, 1.32; 95% CI, 1.04~1.69) showed 
a higher eradication rate than did 7-day standard triple 
therapy.10 Several meta-analyses have demonstrated sim-
ilar results for standard triple therapy.7,9,25 Although the 
eradication rates of standard triple therapy tend to de-
crease, 14-day standard triple therapy could be an ac-
ceptable regimen, since it has a higher therapeutic effect 
than does standard triple therapy with a shorter duration.
The results obtained in our study comparing PBMT and 
SQT are consistent with previous meta-analyses. According 
to the systematic review and meta-analysis study which ana-
lyzed 46 RCTs with 13,532 patients, the overall eradication 
rate of SQT was 84.3% (95% CI, 82.1~86.4%).26 SQT was 
superior to 7-day standard triple therapy (RR, 1.21; 95% CI, 
1.17~1.25) and 10-day standard triple therapy (RR, 1.11; 95% 
CI, 1.04~1.19).26 However, SQT was not superior to 14-day 
standard triple therapy (RR, 1.00; 95% CI, 0.94~1.06) and 
10- or 14-day of bismuth-containing quadruple therapy (RR, 
1.01; 95% CI, 0.95~1.06).26
Two prospective studies comparing PBMT and CT as 
first-line treatment were recently published, and CT 
showed high eradication rates in both studies. A study 
from Spain reported that the eradication rate was 98.0% 
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(95% CI, 94~100%) in a 14-day CT group and 94.4% (95% 
CI, 88.1~100%) in a 10-day PBMT group at ITT analysis 
(P=0.346).27 There was no significant difference in ad-
verse events rates between CT (56.0%) and PBMT (46.3%) 
(P=0.323).27 The other was a Korean study that con-
ducted a prospective open-label randomized trial com-
paring 14-day modified PBMT and 14-day CT.28 The ITT 
eradication rate was 88.2% in a modified PBMT group and 
79.4% in a CT group (P=0.162).28 PP eradication rates 
were 98.4% and 93.1% in the modified PBMT and CT 
groups, respectively (P=0.199).28 Adverse events rates were 
higher in CT (51.5%) than in modified PBMT (33.8%) pa-
tients (P=0.037).28 The adverse event rates of both studies 
were higher in the CT group than in the PBMT group; 
however, it should be considered that the duration of CT 
is longer than that of PBMT in the Spanish study, and the 
Korean study used modified PBMT that was prescribed 
PBMT twice a day. A meta-analysis of 19 clinical trials 
with 2,070 patients reported that a mean ITT cure rate 
was 88% (95% CI, 85~91%) for CT.29
It is already known that adverse events of PBMT are 
common. The adverse events rates of PBMT typically arise 
in 50% or more.30 The rates of adverse events were 67% 
(358/533) in 10-day PBMT, 58% (309/535) in 10-day CT, 
and 47% (252/535) in 14-day standard triple therapy 
groups in a multi-center, randomized trial from Taiwan.15 
Although we observed considerable heterogeneity among 
trials, the adverse events of PBMT were significantly high-
er than in other eradication therapies (RR, 1.64; 95% CI, 
1.11~2.44) in the current meta-analysis. A recent network 
meta-analysis including 35 studies with 10,860 patients 
for demonstrating adverse events reported that PBMT 
showed more adverse events than did SQT and CT.31 
Compared to 14-day PBMT, 14-day SQT (OR, 0.42; 95% CI, 
0.22~0.80), 10-day SQT (OR, 0.49; 95% CI, 0.31~0.78), 
and 10- or 14-day CT (OR, 0.57; 95% CI, 0.37~0.89) 
therapies were significantly lower in the adverse events 
rates.31 There was no significant difference in rates of ad-
verse events between PBMT and standard triple therapy 
groups in other meta-analyses; however, the overall in-
cidence of adverse events was 46% in PBMT and 46.3% in 
the standard triple therapy groups.32 Therefore, the ad-
verse events of PBMT are an issue to consider in clinical 
practice when using PBMT regimens.
Another problem to take account of in prescribing 
PBMT is rescue therapy related. It is difficult to decide on 
a rescue therapy after failure of PBMT. The Maastricht 
V/Florence consensus report recommended a quino-
lone-containing triple or quadruple therapy in patients 
who failed with PBMT.7 In high quinolone-resistance 
areas, it is recommended to use the combination of bis-
muth with other antibiotics.7 The revised Korean guide-
line recommended a rescue regimen containing two or 
more antibiotics that had not been included in PBMT in 
patients with eradication failure for PBMT.3 Given the 
quinolone resistance to H. pylori, the resistance rates of 
both levofloxacin and moxifloxacin revealed a tendency 
to increase time-dependently (4.7~28.1%, P=0.002) in 
Korea.21 A recent Korean study showed that the resist-
ance rates of both levofloxacin and ciprofloxacin were 
37.0%.33 Another study from Korea compared 7-day 
PBMT with 14-day moxifloxacin triple therapy as a sec-
ond-line H. pylori eradication therapy.34 Eradication rates 
were 93.6% (95% CI, 91.0~95.9%) and 73.8% (95% CI, 
63.1~84.6%) in 7-day PBMT and 14-day moxifloxacin tri-
ple therapy groups, respectively (P<0.001).34 Despite the 
shorter duration of PBMT, it exhibited a higher erad-
ication rate than did the longer duration of moxifloxacin 
triple therapy. H. pylori culture and antimicrobial sus-
ceptibility testing are preferred methods to be used after 
eradication failure of PBMT regimens.7 Actually, few labo-
ratories have been installed with these systems in Korea. 
Thus, though PBMT is a valuable treatment for H. pylori 
infection, PBMT as a first-line therapy could be recom-
mended for patients with an allergy to penicillin, with a 
clarithromycin-resistant H. pylori infection, or with a his-
tory of previous macrolide use.
This study has several limitations. First, only a few trials 
were included in our analysis, and heterogeneities among 
studies were generally moderate or high. Therefore, this 
should be considered when interpreting our results. Second, 
studies from Korea could not be analyzed because there are 
no randomized controlled Korean studies on this subject. 
However, several Turkish and Taiwanese studies were in-
cluded in this analysis. Turkey belonged to areas of high 
H. pylori prevalence (77.2%)1 and high clarithromycin resist-
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ance (28%).35 The prevalence of H. pylori infection in Taiwan 
was 53.9%1 and clarithromycin resistance was 26%.35 
Therefore, these results could reflect those in Korea.
In conclusion, PBMT can be a first-line treatment for 
H. pylori eradication when other first-line options are un-
available, because of its high adverse events rate and its 
potential for use as rescue therapy. Further well-designed 
studies are needed to prove the efficacy of PBMT for 
first-line H. pylori eradication in Korea.
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